股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國神威藥業集團有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | 本月底法定/註冊 ...

Group 1 - The company has successfully won bids for eight major products in the national traditional Chinese medicine procurement alliance, covering treatment areas such as cardiovascular diseases, respiratory diseases, and digestive system diseases, which are commonly used in clinical applications and included in medical insurance and essential drug lists [2] - The successful bidding aligns the products with DRG/DIP payment requirements, providing better medication options for more patients and enhancing future market demand, market coverage, and sales potential for the company's products [2] - The traditional Chinese medicine granule industry is entering a period of deep adjustment characterized by declining sales, with the company's sales revenue for traditional Chinese medicine granules decreasing by 14.4% due to multiple policy impacts [2] Group 2 - For the fiscal year ending December 31, 2025, the company reported a revenue of RMB 3.135 billion, a decrease of 17.0% compared to the previous year, with a gross margin of 72.3%, down from 75.0% last year [3] - The annual profit increased by 13.1% to RMB 950 million, with earnings per share at RMB 1.26, and the company declared an interim dividend of RMB 0.43 per share for 2026 [3]

智通财经APP获悉，神威药业(02877)午间发布年度业绩，午后股价拉升逾8%。截至发稿，涨7.87%，报 9.32港元，成交额1069.04万港元。 消息面上，神威药业发布全年业绩，全年收入31.35亿元人民币，同比下降17.0%；年度溢利为9.5亿 元，同比上升13.1%；每股盈利126分人民币。派2026年第一次中期股息每股43分人民币，连同2025年 第二次中期股息每股11分人民币，2025财政年度每股股息共派54分人民币，派息率为42.9%。 公告称，2025年，本集团八个重磅产品一举中标全国中成药采购联盟集中采购，中标产品涵盖了心脑血 管疾病、呼吸系统疾病、消化系统疾病等治疗领域，是临床应用中的最常用的医保、基药品种。此次集 采中标后，中标产品更符合DRG/DIP的支付要求，为更多患者提供优质优价的用药选择，进一步提升本 集团产品未来的终端市场需求、市场覆盖率、和更大的市场销售空间。 ...

Group 1: Company Performance - The company reported a total revenue of RMB 3.135 billion for the fiscal year ending December 31, 2025, representing a 17.0% decrease compared to the previous year [1][4] - The gross profit margin decreased to 72.3% from 75.0% in the previous year [1][4] - The annual profit increased by 13.1% to RMB 950 million, with earnings per share at RMB 1.26 [1][4] - The company declared an interim dividend of RMB 0.43 per share for 2026 [1][4] Group 2: Product and Market Developments - In 2025, the company successfully won bids for eight key products in the national Chinese medicine procurement alliance, covering treatment areas such as cardiovascular, respiratory, and digestive diseases [1][4] - The successful bids align with DRG/DIP payment requirements, enhancing the availability of quality medications at competitive prices for patients, which is expected to boost future market demand and sales [1][4] Group 3: Industry Trends - The traditional Chinese medicine granule industry has entered a period of deep adjustment, characterized by declining sales due to the implementation of national standards, normalization of provincial procurement, and ongoing healthcare cost control [2][5] - The company's sales revenue from traditional Chinese medicine granules decreased by 14.4% during the year [2][5] - The sales team is focused on expanding into target provinces, controlling costs, and enhancing regional and product competitiveness, with expectations of regaining growth as the industry stabilizes [2][5]

Group 1 - The core viewpoint of the articles highlights the financial performance of Shenwei Pharmaceutical (02877), reporting a net profit of RMB 950 million, which represents a year-on-year increase of 13.1% despite a decline in revenue [1] - The company's total revenue for the fiscal year ending December 31, 2025, was RMB 3.135 billion, a decrease of 17.0% compared to the previous year, with a gross margin of 72.3%, down from 75.0% last year [1] - The company declared an interim dividend of RMB 0.43 per share for 2026, with earnings per share reported at RMB 1.26 [1] Group 2 - The traditional Chinese medicine granule industry is experiencing a significant adjustment period characterized by declining sales due to multiple policy impacts, including the implementation of national standards and the normalization of provincial centralized procurement [2] - The sales revenue of the company's traditional Chinese medicine granules decreased by 14.4% during the year, reflecting the overall industry trend [2] - The company is actively working to expand its sales team, control costs, and enhance regional and product competitiveness, with expectations of regaining growth as the industry landscape stabilizes [2]

EF001 免責聲明 第 1 頁 共 2 頁 v 1.1.1 EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，執行董事包括李振江先生、信蘊霞女士及李惠民先生；非執行董事為周文成先生；而獨立非執行董事包括廖舜輝先 生、姚逸安先生及王桂華女士。 第 2 頁 共 2 頁 v 1.1.1 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 中國神威藥業集團有限公司 | | 股份代號 | 02877 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二六年十二月三十一日止年度第一次中期股息 | | 公告日期 | 2026年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 其他 ...

Core Viewpoint - Shenwei Pharmaceutical (02877.HK) reported a significant decline in revenue and gross profit for the fiscal year 2025, reflecting challenges in the traditional Chinese medicine industry due to various external pressures [1] Company Performance - Revenue for the year was RMB 3.135 billion, a decrease of 17.0% compared to the previous year [1] - Gross profit amounted to RMB 2.266 billion, down 20% year-on-year [1] - The profit attributable to shareholders increased by 13.1% to RMB 950 million [1] - Basic earnings per share were RMB 1.26, with a proposed interim dividend of RMB 0.43 per share for 2026 [1] Industry Context - The traditional Chinese medicine industry is undergoing a deep adjustment and value reconstruction period due to five major factors: medical insurance cost control, centralized procurement price reductions, shrinking demand, consumer downgrade, and rising production costs [1] - Overall sales in the industry have declined, with most product revenues experiencing significant decreases during the year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不會就本公佈全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：2877） 二零二五年年度業績公告 及 宣派二零二六年第一次中期股息 中國神威藥業集團有限公司（「本公司」或「神威」）的董事會（「董事會」）欣然提呈本公司及 其附屬公司（統稱「本集團」）截至二零二五年十二月三十一日止年度的經審核綜合業績如 下： 財務概要 截至二零二五年十二月三十一日止年度，本集團錄得下列經營業績： - 1 - • 營業額為人民幣3,135,419,000元，比去年下降17.0%； • 毛利率為72.3% ，而去年為75.0%； • 年度溢利為人民幣949,948,000元，比去年上升13.1%； • 每股盈利為人民幣126分；及 • 宣派二零二六年第一次中期股息每股人民幣43分。 董事會主席報告 尊敬的各位股東： 二零二五年作為本集團「十四五」戰略規劃的收官之年，中藥行業進入結構優化、優勝劣 汰、價值回歸的全新發展階段，行業深度變革的同時迎 ...

Group 1 - The company, Shenwei Pharmaceutical (02877.HK), announced a board meeting scheduled for March 27, 2026, to be held at 31/F, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong [1] - The purpose of the board meeting includes the approval of the annual results for the company and its subsidiaries for the year ending December 31, 2025, as well as the consideration of dividend declaration [1]

( 在開曼群島註冊成立之有限責任公司 ) ( 股份代號： 2877) 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED 中國神威藥業集團有限公司 承董事會命 中國神威藥業集團有限公司 主席 李振江 香港，二零二六年三月十七日 於本公告刊發日期，執行董事包括李振江先生、信蘊霞女士及李惠民先生。非執行董事為周 文成先生。獨立非執行董事包括廖舜輝先生、姚逸安先生及王桂華女士。 董事會會議通告 中國神威藥業集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 二零二六年三月二十七日星期五於香港灣仔港灣道18號中環廣場31樓3109室舉行董事 會會議，藉以（其中包括）批准發佈本公司及其附屬公司截至二零二五年十二月三十 一日止年度業績及考慮宣派股息。 ...